drugset / Trial / NCT01313208

Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)

NCT01313208

Phase 4 Completed 210 enrolled Amgen
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is designed to evaluate the effectiveness of adding etanercept to disease modifying anti-rheumatic drug (DMARD) therapy in patients with moderately active Rheumatoid Arthritis (RA).

Timeline

Start
2011-03
Primary completion
2013-02
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 50 mg Subcutaneous
Background Hydroxychloroquine Small molecule
Background Leflunomide Small molecule
Background Methotrexate Small molecule
Background Minocycline Small molecule
Background Sulfasalazine Small molecule

Indications